Related Experiment Video
Updated: Apr 12, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.7K
An Update on Pulmonary Arterial Hypertension
Joanna Wapner1, Lea Ann Matura2
1University of Pennsylvania, 2101 Market Street Unit 804, Philadelphia PA 19103.
The Journal for Nurse Practitioners : JNP
|May 9, 2015
Summary
Pulmonary arterial hypertension (PAH) is a serious condition leading to heart failure. Diagnosis involves excluding other conditions through various tests, and nurse practitioners play a key role in managing PAH patient care.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Nursing
Background:
- Pulmonary arterial hypertension (PAH) is a progressive condition.
- PAH can lead to right heart failure and death.
- Accurate diagnosis is crucial for effective management.
Purpose of the Study:
- To define Pulmonary Arterial Hypertension (PAH).
- To outline diagnostic methods for PAH.
- To emphasize the role of nurse practitioners in PAH care.
Main Methods:
- Diagnosis by exclusion.
- Utilizing patient history and serology.
- Employing imaging and functional tests like chest radiograph, pulmonary function tests, V/Q scan, echocardiogram, and right heart catheterization.
Main Results:
- PAH is defined by specific hemodynamic parameters (mean pulmonary arterial pressure ≥ 25 mm Hg, pulmonary capillary wedge pressure ≤ 15 mm Hg).
- Diagnosis requires a comprehensive exclusion process.
- Treatment and care are complex, necessitating a multidisciplinary approach.
Conclusions:
- Nurse practitioners are essential members of the healthcare team for PAH patients.
- Seamless care and support are vital for managing PAH.
- Effective management relies on accurate diagnosis and integrated patient care.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
880
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
880
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
788
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
788
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
766
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
766
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
661
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
568
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
568
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
617
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
617